GlassScriptPhysician profile
Abdullah A Alwahdani
NPI 1952478620
$1,582.87
in general payments reported to CMS, 2019-2025
16 companies · $43.31 in 2025
The $43.31 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.36 · 2020: $15.29 · 2021: $172 · 2022: $314 · 2023: $587 · 2024: $424 · 2025: $43.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670 · Education: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.69 |
| Education | $383.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $383.98 | 2023 | |
| Shockwave Medical, INC | $381.75 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $346.06 | 2021-2024 | |
| Edwards Lifesciences Corporation | $82.04 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $78.54 | 2019-2023 | Xarelto |
| Medtronic, INC. | $70.29 | 2021-2023 | In.Pact Admiral |
| Chiesi USA, INC. | $48.95 | 2021-2023 | Kengreal |
| Abbott Laboratories | $42.64 | 2023-2024 | Esprit, Perclose Proglide |
| Pfizer INC. | $28.64 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.98 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $18.33 | 2023 | Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.05 | 2023 | Jardiance |
| Covidien LP | $15.29 | 2020 | |
| Teleflex LLC | $14.41 | 2023 | Supercross |
| Bard Peripheral Vascular, INC. | $14.02 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.90 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Alwahdani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.